TVTX
Closed
Travere Therapeutics Inc
21.1
+0.9 (+4.45%)
Last Update: 05 Feb 2025 00:00:00
Yesterday: 20.22
Day's Range: 20.06 - 21.2
Send
sign up or login to leave a comment!
When Written:
20.98
Travere Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in January 2021. Travere Therapeutics is headquartered in San Diego, California, and has operations in Europe and Canada.
The company's portfolio includes treatments for rare diseases such as nephrotic syndrome, focal segmental glomerulosclerosis (FSGS), and PKAN (pantothenate kinase-associated neurodegeneration). The company's lead product candidate, sparsentan, is being developed for the treatment of FSGS and IgA nephropathy.
Travere Therapeutics was founded in 2011 by Martin Shkreli, who later became infamous for his role in raising the price of a life-saving drug. The company went public in 2013 and has since expanded its focus to rare diseases. Travere Therapeutics has partnerships with various organizations, including the National Kidney Foundation and the University of Michigan.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company's portfolio includes treatments for rare diseases such as nephrotic syndrome, focal segmental glomerulosclerosis (FSGS), and PKAN (pantothenate kinase-associated neurodegeneration). The company's lead product candidate, sparsentan, is being developed for the treatment of FSGS and IgA nephropathy.
Travere Therapeutics was founded in 2011 by Martin Shkreli, who later became infamous for his role in raising the price of a life-saving drug. The company went public in 2013 and has since expanded its focus to rare diseases. Travere Therapeutics has partnerships with various organizations, including the National Kidney Foundation and the University of Michigan.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!